Results 231 to 240 of about 476,060 (306)
Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H [PDF]
Christophe Marchand+8 more
openalex +1 more source
Multi‐Omics and ‐Organ Insights into Energy Metabolic Adaptations in Early Sepsis Onset
This study shows that patients at risk of sepsis have a distinct metabolite and lipid signature, including serine and aminoadipic acid, in their serum before clinical diagnosis. A mouse model of sepsis with a compatible serum signature reveals underlying metabolic changes, including mitochondrial adaptation, altered serine‐dependent purine metabolism ...
Lin‐Lin Xu+9 more
wiley +1 more source
RNase H activity: Structure, specificity, and function in reverse transcription [PDF]
Sharon J. Schultz, James J. Champoux
openalex +1 more source
Multiscale Organization of Neural Networks in a 3D Bioprinted Matrix
A 3D bioprint model of primary neurons has been engineered with a millimeter‐scale functional neural network, and it recapitulates in vivo transcriptomic features under both normal and disease conditions to the greatest extent. The successful integration of mature neurons and 3D bioprinting signifies a major advance in neuroscience modeling ...
Huiyu Yang+16 more
wiley +1 more source
Synthesis, biophysical properties, and RNase H activity of 6'-difluoro[4.3.0]bicyclo-DNA. [PDF]
Frei S, Katolik AK, Leumann CJ.
europepmc +1 more source
Upregulated glycosyltransferase GALNT9 in neuroendocrine (NE) carcinomas increases O‐GalNAc glycosylation on cell membrane proteins, particularly Annexin‐A2 (ANXA2). Elevated O‐GalNAc glycan induces the binding of NE cancer cells to mannose binding lectin 2 (MBL2), activating the MBL‐MBL associated serine protease (MBL‐MASP) complement pathway in the ...
Xinyu Chen+24 more
wiley +1 more source
3-Hydroxypyrimidine-2, 4-dione Derivatives as HIV Reverse Transcriptase-Associated RNase H Inhibitors: QSAR Analysis and Molecular Docking Studies. [PDF]
Mostoufi A+4 more
europepmc +1 more source
To overcome pancreatic cancer's immunosuppressive barriers, this study explores a dual approach: triggering immunogenic tumor cell death at the primary tumor site with irinotecan‐loaded silicasomes and enhancing immune activation in the spleen using LNPs encapsulating tumor antigen mRNA and a TLR7/8 agonist.
Lijia Luo+3 more
wiley +1 more source